BR112018075396A2 - anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika - Google Patents

anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika

Info

Publication number
BR112018075396A2
BR112018075396A2 BR112018075396-3A BR112018075396A BR112018075396A2 BR 112018075396 A2 BR112018075396 A2 BR 112018075396A2 BR 112018075396 A BR112018075396 A BR 112018075396A BR 112018075396 A2 BR112018075396 A2 BR 112018075396A2
Authority
BR
Brazil
Prior art keywords
residues
flaviviruses
zika
denv
virus
Prior art date
Application number
BR112018075396-3A
Other languages
English (en)
Inventor
Rey Félix
Barba Spaeth Giovanna
Vaney Marie-Christine
Rouvinski Alexander
Screaton Gavin
MONGKOLSAPAYA Juthathip
Original Assignee
Imperial Innovations Ltd
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd, Institut Pasteur filed Critical Imperial Innovations Ltd
Publication of BR112018075396A2 publication Critical patent/BR112018075396A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

trata-se de um epítopo de dímero de envelope (ede) de flavivírus para uso em vacinação de um indivíduo contra um ou mais flavivírus em que o ede é um flavivírus recombinante estabilizado, opcionalmente dímero de ectodomínio e (se) de glicoproteína de envelope de zika e/ou vírus da dengue, em que o dímero é: covalentemente estabilizado com pelo menos uma ligação intercadeia de dissulfeto entre os dois monômeros de se, e/ou não covalentemente estabilizado com a substituição de pelo menos um resíduo de aminoácido na sequência de aminoácidos de pelo menos um monômero de se por pelo menos um aminoácido de cadeia lateral volumoso na interface de dímero ou no ligante de domínio 1 (d1)/domínio 3 (d3) de cada monômero, covalentemente estabilizado com pelo menos um reticulador reativo à sulfidrila entre os dois monômeros de se, e/ou covalentemente estabilizado através da formação como uma cadeia de polipeptídeos única, opcionalmente com uma região de ligante, opcionalmente uma região de ligante rica em serina e glicina, que separa as sequências de se, e/ou covalentemente estabilizado pela ligação dos dois monômeros de se através de açúcares modificados; e/ou, em que o dímero é um homodímero ou heterodímero de polipeptídeos de envelope mutantes e/ou nativos, de qualquer um ou dois dentre denv-1, denv-2, denv-3, denv-4, zika ou outros flavivírus; e em que o um ou mais flavivírus são selecionados a partir de vírus da zika; vírus da zika e vírus da dengue; vírus da zika e outros flavivírus; flavivírus além da dengue. o ede pode ser um homodímero ou heterodímero de polipeptídeos de envelope mutantes e/ou nativos de qualquer um ou dois dentre denv-1, denv-2, denv-3, denv-4 e zika. anticorpo neutralizante isolado ou fragmento de ligação ao antígeno direcionado contra o ede, conforme definido em qualquer uma das reivindicações 1 a 29, em que, opcionalmente, o dito anticorpo ou fragmento do mesmo liga os cinco segmentos de polipeptídeo do ectodomínio e (se) de glicoproteína de vírus da dengue que consistem nos resíduos 67 a 74, resíduos 97 a 106, resíduos 307 a 314, resíduos 148 a 159 e resíduos 243 a 251 ou resíduos correspondentes do ectodomínio e de glicoproteína de vírus da zika ou flavivírus ou que consistem em zika pf13 resíduos 67 a 77, resíduos 97 a 106, resíduos 313 a 315, resíduos 243 a 253, resíduo k373 ou resíduos correspondentes do ectodomínio e de glicoproteína de flavivírus, em que, opcionalmente, a ligação não é afetada pela presença ou ausência de glicano de dengue n153 (zika n154) ou resíduo correspondente, para uso em um método para prevenção e/ou tratamento de infecção por um ou mais flavivírus, em que o um ou mais flavivírus são selecionados a partir de vírus da zika; vírus da zika e vírus da dengue; vírus da zika e outros flavivírus; flavivírus além da dengue.
BR112018075396-3A 2016-06-10 2017-06-09 anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika BR112018075396A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1610162.8A GB201610162D0 (en) 2016-06-10 2016-06-10 Methods
GB1610162.8 2016-06-10
PCT/GB2017/051692 WO2017212291A1 (en) 2016-06-10 2017-06-09 Neutralising antibody against dengue for use in a method of prevention and/or treatment of zika infection

Publications (1)

Publication Number Publication Date
BR112018075396A2 true BR112018075396A2 (pt) 2019-03-19

Family

ID=56894660

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075396-3A BR112018075396A2 (pt) 2016-06-10 2017-06-09 anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika

Country Status (8)

Country Link
US (2) US11111274B2 (pt)
EP (1) EP3468591A1 (pt)
JP (1) JP2019523647A (pt)
BR (1) BR112018075396A2 (pt)
CA (1) CA3066488A1 (pt)
GB (1) GB201610162D0 (pt)
MX (1) MX2018015343A (pt)
WO (1) WO2017212291A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193868A1 (en) 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019090233A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
KR20200090893A (ko) 2017-11-30 2020-07-29 다케다 백신즈 인코포레이티드 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US20210308250A1 (en) * 2018-10-26 2021-10-07 New York Blood Center, Inc. Zika virus immunogenic compositions
WO2020242388A1 (en) * 2019-05-28 2020-12-03 Chiang Mai University Mature virus-like particles of flaviviruses
TWI756812B (zh) * 2019-09-03 2022-03-01 財團法人國家衛生研究院 廣效性蚊媒黃病毒疫苗及其用於誘發中和性抗體的用途
JP7471555B2 (ja) 2020-02-20 2024-04-22 国立感染症研究所長 フラビウイルス交差中和抗体及び医薬組成物
WO2023235660A2 (en) * 2022-05-17 2023-12-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Flavivirus immunogens and vaccine compositions and methods of using the same
WO2024081625A1 (en) * 2022-10-11 2024-04-18 University Of Maryland, Baltimore Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2576798C (en) 2004-07-27 2014-09-09 Gwong-Jen J. Chang Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods

Also Published As

Publication number Publication date
MX2018015343A (es) 2019-11-18
US20210355167A1 (en) 2021-11-18
US20190256560A1 (en) 2019-08-22
EP3468591A1 (en) 2019-04-17
CA3066488A1 (en) 2017-12-14
JP2019523647A (ja) 2019-08-29
WO2017212291A1 (en) 2017-12-14
US11111274B2 (en) 2021-09-07
GB201610162D0 (en) 2016-07-27
US11926648B2 (en) 2024-03-12

Similar Documents

Publication Publication Date Title
BR112018075396A2 (pt) anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika
BR112017001340A2 (pt) vacinas antidengue e anticorpos
BR112015032875A2 (pt) derivados de peptídeos do tipo glp-1, e usos dos mesmos
BR112018007318A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, e, métodos para tratar uma doença ou condição.
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
RU2021124437A (ru) Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
CY1119976T1 (el) Μιμητικα καλσιτονινης για την αντιμετωπιση ασθενειων και διαταραχων
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
PE20221909A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
BR112018071686A2 (pt) exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
BR112017019191A2 (pt) métodos para reduzir níveis de soro de agentes que contêm fc utilizando antagonistas de fcrn
PE20210043A1 (es) Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo
BR112018007154A2 (pt) polipeptídeo de ligação a pd-l1, proteína de fusão ou conjugado, complexo, polinucleotídeo, e composição
BR112015021341A2 (pt) anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos
BR112018007960A2 (pt) conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado.
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
PE20190371A1 (es) Anticuerpos de interferon beta y usos de los mismos
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
PE20181956A1 (es) Polipeptidos que inhiben cd40l
BR112019003462A2 (pt) proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B25G Requested change of headquarter approved

Owner name: INSTITUT PASTEUR (FR) ; IMPERIAL INNOVATIONS LTD (GB)

B25A Requested transfer of rights approved

Owner name: INSTITUT PASTEUR (FR) ; IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]